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Neurobiology of Disease
Periaqueductal Grey EP3 Receptors Facilitate Spinal
Nociception in Arthritic Secondary Hypersensitivity
XR.A.R. Drake,1 J.L. Leith,1 F. Almahasneh,2 J. Martindale,3 A.W.Wilson,3 XB. Lumb,1
and XL.F. Donaldson1,2
1School of Physiology and Pharmacology, University of Bristol, Bristol BS8 1TD, United Kingdom, 2Arthritis Research UK Pain Centre and School of Life
Sciences, University of Nottingham, Nottingham NG7 2UH, United Kingdom, and 3Neurosciences CEDD, GlaxoSmithKline, Harlow CM19 5AW, United
Kingdom
Descending controls on spinal nociceptive processing play a pivotal role in shaping the pain experience after tissue injury. Secondary
hypersensitivity develops within undamaged tissue adjacent and distant to damaged sites. Spinal neuronal pools innervating regions of
secondary hypersensitivity are dominated by descending facilitation that amplifies spinal inputs from unsensitized peripheral nocicep-
tors. Cyclooxygenase–prostaglandin (PG) E2 signaling within the ventrolateral periaqueductal gray (vlPAG) is pronociceptive in naive
and acutely inflamed animals, but its contributions in more prolonged inflammation and, importantly, secondary hypersensitivity
remain unknown. In naive rats, PGEP3 receptor (EP3R) antagonism in vlPAGmodulated noxiouswithdrawal reflex (EMG) thresholds to
preferential C-nociceptor, but not A-nociceptor, activation and raised thermal withdrawal thresholds in awake animals. In rats with
inflammatory arthritis, secondary mechanical and thermal hypersensitivity of the hindpaw developed and was associated with spinal
sensitization to A-nociceptor inputs alone. In arthritic rats, blockade of vlPAGEP3R raised EMG thresholds to C-nociceptor activation in
the area of secondary hypersensitivity to a degree equivalent to that evoked by the samemanipulation in naive rats. Importantly, vlPAG
EP3R blockade also affected responses to A-nociceptor activation, but only in arthritic animals. We conclude that vlPAG EP3R activity
exerts an equivalent facilitation on the spinal processing of C-nociceptor inputs in naive and arthritic animals, but gains in effects on
spinal A-nociceptor processing from a region of secondary hypersensitivity. Therefore, the spinal sensitization to A-nociceptor inputs
associated with secondary hypersensitivity is likely to be at least partly dependent on descending prostanergic facilitation from the
vlPAG.
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Introduction
The midbrain periaqueductal gray (PAG) and downstream nu-
clei within the medulla and brainstem, such as the rostroventral
medulla, form a descending pain modulatory system that can
augment or inhibit spinal processing of nociceptive information.
This system affects pain experience by regulating the spinal pro-
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Significance Statement
After tissue damage, sensitivity to painful stimulationdevelops in undamaged areas (secondary hypersensitivity). This is found in
many painful conditions, particularly arthritis. The periaqueductal gray (PAG) is an important center that controls spinal noci-
ceptive processing, on which secondary hypersensitivity depends. Prostaglandins (PGs) are mediators of inflammation with
pronociceptive actionswithin thePAGundernormal conditions.We find that secondaryhindpawhypersensitivity in arthritic rats
results from spinal sensitization to peripheral A-nociceptor inputs. In the PAG of arthritic, but not naive, rats, there is enhanced
control of spinal A-nociceptor processing through PG EP3 receptors. The descending facilitatory actions of intra-PAG PGs play a
direct and central role in the maintenance of inflammatory secondary hypersensitivity, particularly relating to the processing of
A-fiber nociceptive information.
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cessing of nociceptive inputs and the subsequent transmission of
nociceptive information to the brain (Millan, 2002).
The balance of descending inhibitory and facilitatory control
of spinal nociceptive processing contributes to the enhanced pain
that develops after tissue injury. For example, sensitization to
noxious stimulation can develop within undamaged tissue adja-
cent/distant to the damaged site, termed secondary hypersensi-
tivity (also discussed as secondary hyperalgesia and/or allodynia;
Treede and Magerl, 2000; Tracey and Mantyh, 2007). Spinal
dorsal horn neurons that have receptive fields within the region
of secondary hypersensitivity (referred to as “secondary sites”
herein) are subject to both descending facilitatory and inhibi-
tory controls from the midbrain. However, facilitation often ex-
erts more influence than inhibition on inputs from secondary
sites (Urban et al., 1996; Vanegas and Schaible, 2004). Maladap-
tation of these descending controls, resulting in net facilitation,
is a major contributor to the development and maintenance of
chronic pain (De Felice et al., 2011; Staud, 2013).
Prostaglandin E2 (PGE2) is a lipid signaling molecule with
well described peripheral and spinal functions in nociception,
particularly in inflammatory arthritis (Vanegas and Schaible,
2001; Korotkova and Jakobsson, 2014). One identified, but not
yet fully characterized, tonic descending facilitatory system from
the PAG uses endogenous PGs (Leith et al., 2007). Cyclooxygen-
ase (COX) enzymes, key enzymes in the production of PGs, and
all four PGE2 receptors, known as EP receptors 1–4 (Kennedy et
al., 1982), are reportedly expressed in the PAG (Breder et al.,
1992; Breder et al., 1995; Vaughan, 1998; Oliva et al., 2006;
Palazzo et al., 2011; Myren et al., 2012). Unfortunately, complete
information on cellular localization is not available due to a lack
of available high-quality, specific antibodies (Myren et al., 2012).
The endogenous tonic COX-1-PGE2 systemwithin the ventrolat-
eral PAG (vlPAG) primarily facilitates spinal processing of
C-nociceptor inputs in naive rats, in that PGE2 injection in the
vlPAG produces hyperalgesia (Heinricher et al., 2004; Leith et al.,
2007) andCOX-1 inhibition in the PAG results in analgesia (Tor-
torici andVanegas, 1995; Leith et al., 2007). EP receptor signaling
in the PAG contributes to both acute primary inflammatory hy-
peralgesia and neuropathic pain in the rat (Oliva et al., 2006;
Palazzo et al., 2008).
PGE2 signaling within the vlPAG modulates ON cell activity
within the rostral ventral medulla (RVM) (Heinricher et al.,
2004), an important area controlling both descending facilitation
and inhibition of the spinal cord (Heinricher et al., 2009). The
RVM is critical in the development of secondary hypersensitivity
(Urban et al., 1999; Vanegas, 2004; Ambriz-Tututi et al., 2011).
However, the contribution of the PG/COX descending facili-
tatory system to secondary hypersensitivity is not known. Sys-
temic nonsteroidal anti-inflammatory drugs (NSAIDs), which
inhibit COX activity, can block sensitization in secondary sites in
both humans and animal models (Petersen et al., 1997; Koppert
et al., 2004; Stubhaug et al., 2007).
A-nociceptors andC-nociceptors play distinct roles in the ini-
tiation and maintenance of secondary hypersensitivity, respec-
tively (Ziegler et al., 1999), and in the perceived quality of pain
(Torebjo¨rk, 1985). Peripheral C-nociceptors innervating joints
in inflammatory arthritis are sensitized and display dramatically
altered properties (Schaible et al., 2009). The resulting increase in
C-nociceptor drive is hypothesized to sensitize central neurons to
A-nociceptor inputs from secondary sites of undamaged tissue,
resulting in secondary, usually mechanical, hypersensitivity
(Ziegler et al., 1999; Magerl et al., 2001; You et al., 2010). How-
ever, our understanding of the additional contribution of descend-
ing systems to enhanced spinal A-nociceptor processing and the
impact of this on secondary hypersensitivity remains limited.
In this study, we hypothesized that facilitatory vlPAG PG sig-
naling through intra-PAG EP3 receptors (EP3Rs) contributes to
secondary hypersensitivity of the hindpaw by augmenting the
spinal processing of A-nociceptor, but not C-nociceptor, inputs
from undamaged tissue.
Materials andMethods
Animal preparation
A total of 125maleWistar rats (250–350 g)were used for all experiments.
Any experimental animals subsequently excluded from analysis, and the
reasons for doing so, are noted in the experimental procedures below. All
procedures were performed in laboratories at the University of Bristol
and Glaxo-Smith-Kline (GSK) in accordance with the UK Animals (Sci-
entific Procedures) Act of 1986 plus associated guidelines and with the
approval of the University of Bristol and GSK Ethical Review Groups.
Animals were housed at 21°C and 55% relative humidity with a 12 h
light/dark cycle. Food and water were provided ad libitum.
Implantation of chronic intracerebral guide cannulae
Intracerebral cannulae were implanted in 20 naive male rats. Anesthesia
was induced with 3–5% isofluorane in O2 and then maintained at 1–2%
via a nose cone placed around the snout. Once anesthetized, all animals
received antibiotic treatment (1.0 ml/kg subcutaneous Synulox (clavu-
lanic acid 35 mg/ml and amoxicillin 140 mg/ml; Pfizer) and preemptive
analgesia with 0.4 ml of Rimadyl (carprofen50 mg/ml; Pfizer). Body
temperature was maintained within physiological limits by means of a
feedback-controlled heating blanket and rectal probe. Animals were then
positioned in a stereotaxic frame and a guide cannula implanted into the
PAG. A craniotomy was performed over the periaqueductal gray using a
small hand-held drill (RS Components) fitted with a fine dental burr.
Three further holes were drilled through the skull and screws inserted to
provide stability for the guide cannula once in place. A stainless steel
guide cannula (26 gauge, with the cannula cut 8 mm below the pedestal;
tubing inner diameter 0.24 mm, outer diameter 0.46 mm; part number
C315G, Plastics One) was slowly lowered into the brain aimed at the left
vlPAG (coordinates relative to bregma were 7.4–7.5 mm caudal, 0.9 mm
left of the midline, 6.5 mm below the skull surface). The guide cannula
was then secured to the skull and screws with cyanoacrylate gel (RS
Components). The area was thoroughly cleaned and the incision closed
using absorbable suture (Ethicon Vicryl Rapide 4-0; Johnson & John-
son). A stylet cut to the same length as the implanted cannula (part
number C315DC; Plastics One) was inserted into the implanted cannula
and screwed tightly onto the cannula tomaintain its patency until behav-
ioral testing. After surgical procedures, animals received saline rehydra-
tion (5 ml subcutaneously) and were placed in a warmed environment
until recovery of the righting reflex. Animals were then housed singly to
minimize damage to the implanted cannula assembly and overlying
wound and received 5 d of postoperative care consisting of soft paper
bedding, a soft wet diet, and monitoring of body weight. No further
experimental procedures were undertaken for at least 5 d and until pre-
operative body weight had been achieved.
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Experimental protocol for microinjection of drugs into the PAG
and nociceptive behavioral testing in naive animals
Baseline paw withdrawal thresholds to a linear thermal ramp stimulus
(22–50°C ramp at 1°C/s delivered to the plantar paw surface using a
Peltier device (contact area 3  4 cm) to the left hindpaw; equipment
built in-house at GSK) were measured three times (Leith et al., 2014).
The temperature at which the paw was withdrawn from the thermal
stimulus was taken as the end point. A minimum of 30 min was left
between repeated thermal stimuli on the same animal.
Animals were assigned randomly into two experimental groups (each
n 10) for drug administration. Compounds were administered via the
implanted guide cannula, vehicle (30% DMSO in physiological saline),
or GW671021B (EP3R antagonist; 250 nM), as used previously (Leith et
al., 2007; Leith et al., 2014), in a total volume of 300 nl. The experimenter
was blinded to the identity of the drug administered during the testing
phase. Compounds were injected into the PAG using an internal “injec-
tor” guide cannula cut to project 0.5 mm beyond the end of the
implanted guide cannula (Plastics One) connected to a 1l syringe (Sci-
entific Glass Engineering). Animals were held securely and the stylet
removed from the implanted guide cannula. Compounds were injected
over 1min and the injectorwas left in place for an additionalminute after
the completion of the injection to prevent backflow of the compound up
the cannula. The stylet was then replaced into the implanted cannula.
Paw withdrawal thresholds to the thermal ramp device were tested again
30 min after drug administration. At the end of the behavioral experi-
ments, animals were killed by placement in an enclosure containing nor-
mal roomair andwere subject to a rising concentration of carbondioxide
gas, followed by confirmation of death by cessation of the circulation.
Brains were removed and fixed in 4% paraformaldehyde in 0.1 M phos-
phate buffer for at least 24 h, then cryoprotected in 30% sucrose solution
for at least 24 h, before sectioning at 60 m. PAG injection sites were
localized with reference to a rat brain atlas (Paxinos and Watson, 2006).
Animals in which the cannula was found to have been outwith the vlPAG
were used as a control for the regional effect of drug injection (n  3).
Animals receiving vehicle injection outside of the PAG were excluded
(n  4). Data from the vehicle-injected animals have been described
previously for comparison with intra-PAG ketoprofen injection (Leith et
al., 2014).
Experimental protocol for induction of secondary inflammatory
hypersensitivity, nociceptive behavioral testing, and acute
electrophysiological study
Inflammation was induced in a total of 50 animals. To induce second-
ary hyperalgesia of the hindpaw, animals received a single 100 l
intra-articular injection of complete Freund’s adjuvant (CFA; 1 mg/
ml; catalog #F5881, Sigma-Aldrich) into the left knee intra-articular
space using a U100 needle (29G, U100, Terumo) under isoflurane
anesthesia (2–3% in O2).
In a subset of the arthritic animals (n 11) at 7 d after CFA, the knee
width (n  7) and the hindpaw thickness (n  5) of the inflamed limb
was measured using micrometer calipers (Camlab) and compared with
measurements taken from age-matched naive animals (n  5) to assess
the extent of tissue edema. Before induction and 1, 3, and 7 d after
intra-articular injection, 7 CFA animals also underwent nociceptive test-
ing to assess the development of hindpaw secondary hyperalgesia/
allodynia. Animals were habituated to the holding apparatus and exper-
imenter beginning 3 d before the start of testing. For thermal hyperalgesia
testing, the Hargreaves apparatus (Ugo Basile) was used to assess the
development of thermal hyperalgesia after inflammation (Hargreaves et
al., 1988). The latency to withdrawal from the radiant heat source di-
rected onto the plantar surface of the left hindpaw was recorded and
compared before and after inflammation. On the baseline testing day,
animals were allowed to habituate to the chamber for 5–10 min before
testing began. The radiant heat source was placed directly below the
plantar surface and hindfoot behind the footpad. The intensity of the
radiant heat source was adjusted so that animals gave withdrawal laten-
cies at 12 2 s. Three consecutivemeasurements were recorded and then
averaged to give the withdrawal latency for that animal. An interstimulus
interval (ISI) of at least 8 min was allowed to prevent sensitization. On
experimental testing days, the same intensity of radiant heatwas used and
three consecutive recordings were made and averaged. We saw no evi-
dence of acute or chronic sensitization of the hindpaw to thermal stim-
ulation at this ISI (see Fig. 3, which shows stable withdrawal latencies
between 1 and 7 d and very little variation in latency at each tested time).
For mechanical hyperalgesia/allodynia testing, von Frey hairs (Ugo
Basile) were used to deliver a known gram force to the middle of the
plantar surface of the left hindpaw (middle of foot pad). Each hair was
applied five times in an ascending order of force and the occurrence of a
withdrawal (or display of nocifensive behavior) recorded. The delivery of
a stimulus was stopped immediately after withdrawal/occurrence of no-
cifensive behavior. The percentage of withdrawals evoked by each hair
was then calculated (between 0% and 100%). A stimulus–response curve
was generated by application of a range of forces (typically 0.6–60 g) to
give a full stimulus response curve from 0% to 100%. Stimulus–response
curves were plotted for each animal, at each time point, and the 50%
withdrawal threshold calculated as grams. These values were then com-
pared across the inflammatory period. The distribution of weight across
the hind limbs was measured using an incapacitance meter (incapaci-
tance tester, Linton Instrumentation; Kobayashi et al., 2003) in 11 ani-
mals. Animals were habituated to a Perspex box that positioned animals
so that the hindpaws rested on two force transducers. The forepaws were
supported on an inclined Perspex slope. The weight distributed on the
left leg was calculated as a percentage of the total weight distributed
across both hind limbs. Two consecutive readings were taken at each
experimental time point and the mean calculated. The proportion of
total body weight borne on the hindpaws did not vary significantly over
the course of the experiment.
Acute electrophysiological experiments in naive and
arthritic animals
A total of 42 naive and 60 arthritic animals were used in these experi-
ments. In 15 arthritic animals, EMGexperiments could not be performed
due unattainable or unstable baseline EMG thresholds and these were
excluded from further analyses. All surgical preparation was performed
under initial isoflurane anesthesia (2–3% in O2) and consisted of: (1)
external jugular branch cannulation for anesthetic maintenance, (2) ex-
ternal carotid artery branch cannulation for blood pressure measure-
ment, and (3) tracheal cannulation to maintain clear airways. Once an
intravenous anesthetic line had been established, anesthesiawas switched
to a continuous infusion of alphaxalone diluted in physiological saline
(1:2;40mg/kg/h; Alfaxan, Jurox) for the remainder of the experiments.
Body temperature wasmaintained within physiological limits (37–38°C)
bymeans of a feedback-controlled heatingmat and rectal probe. Animals
were then placed in a stereotaxic frame and a craniotomy was performed
over the caudal PAG (7.56 to7.92 mm from bregma) using a dental
drill (RS Components) and burr (catalog #014; Emile Lange) to allow for
delivery of drugs to the PAG. Some animals (n  21) also received a
laminectomy of lumbar vertebrae 1 and 2 and thoracic vertebra 13 to
allow for electrophysiological extracellular recordings of spinal dorsal
horn neurons.
Recording of EMG activity in terminally anesthetized animals
Evoked thresholds for EMG activity recorded in the hindleg bicep fem-
oris was assessed and used to quantitate noxious thermal withdrawal
thresholds in 39 naive and 24 arthritic anesthetized animals (subsets of
the total number of animals given above). For EMG recordings, a
custom-made bipolar electrode was made from Teflon-coated steel wire
(0.075 mm diameter; Advent Research Materials) and inserted into the
bicep femoris of the left hindleg. The signal across the electrodes was
amplified (x1K, A-B configuration; Neurolog NL104 amplifier, Digi-
timer), filtered (50 Hz–5 kHz, NL125, Neurolog), and raw data digitized
via a CED 1401 and stored for off-line analysis using Spike2 (CED).
Recording of dorsal horn neuronal activity in terminally
anesthetized animals
Extracellular recordingsweremade of spinalwide dynamic range (WDR)
neurons in 21 arthritic animals (a subset of the total number of animals
given above) under continuous alphaxalone anesthesia. The vertebral
columnwas clamped on the vertebrae dorsal processes at each end of the
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laminectomy and at the lateral edges of the vertebral column around the
recording site to stabilize the preparation. To locate the spinal site to
perform electrophysiological recordings, spinal neuronal activity was
electrically evoked (5V, 0.1ms, 0.1Hz) from the contralateral hindpaw
dorsum using subcutaneous bipolar stimulating electrodes. A low im-
pedance ball electrode was tracked along the rostrocaudal extent of the
exposed spinal cord and used to determine the location at which maxi-
mum dorsum potentials could be recorded. Once the site was deter-
mined, the dura was removed, a poolmadewith skin flaps, and the whole
area filled with agar to further stabilize the preparation and to prevent
excessive loss of tissue fluid. Once set, a recording windowwas cut out of
the agar over the desired recording site and filled with warm paraffin oil.
Using an electronic microstepper, a tungsten microelectrode (5 M;
Microprobes) (Merrill and Ainsworth, 1972) was lowered into the cord
at the rostrocaudal location at which maximum dorsum potentials had
been observed. Single-unit neuronal activity was amplified (x5K, A-B
configuration, Neurolog NL104, Digitimer), filtered (300–5000 Hz,
NL125, Digitimer), passed through a 50 Hz noise eliminator (Hum-Bug,
Quest Scientific), and the raw data digitized via a CED 1401 and captured
by a computer running Spike5 software.
Preferential A- and C-nociceptor activation
A- and C-heat nociceptors were activated preferentially using a custom-
made heat lamp placed in contact with dorsal surface of the hindpaw
(McMullan et al., 2004; Leith et al., 2007; Leith et al., 2014). This is a
noninvasive method for preferential activation of either C-nociceptors
(with slow rates of contact skin heating) or A-nociceptors (with fast rates
of heating). The rates of skin heating used here reliably reproduce the
same subcutaneous heating rates as those described previously that pref-
erentially activate A- versus C-nociceptors at the single-fiber level (Yeo-
mans and Proudfit, 1996; McMullan et al., 2004; Leith et al., 2007). One
advantage of this noninvasive preferential activation method is the re-
moval of the potential confound of different stimulus modalities used to
activate different sensory neurons (thermal/mechanical) from the inter-
pretation of the findings. This method also activates populations of neu-
rons rather than individual fibers using a more physiological stimulus
than, for example, electrical stimulation. It should be borne in mind,
however that this method is a preferential activation and not a selective
activation of different afferent groups. Briefly, a custom-built stainless
steel casing positioned a sputter-coated 12 V bulb (halogen lamp, 15 v,
150w; Phillips) over a copper disk (contact area 45mm2) that was placed
in contact with the surface of the paw. A constant voltage was applied to
the lamp to provide fast (7.5  1°C/s) or slow rates of heating (2.5 
1°C/s), which activate A-fiber (myelinated, capsaicin-insensitive) and
C-fiber (unmyelinated, capsaicin-sensitive) heat nociceptors preferen-
tially, respectively (McMullan et al., 2004; Leith et al., 2007). A T-type
thermocouple attached to the copper disk was used to monitor temper-
ature at the heat lamp–skin border during heating. The heat ramp appa-
ratus was placed in contact with the paw for at least 60 s before the start of
heating to allow for adaptation of low-threshold mechanoreceptors.
Stimuli were delivered with an ISI of at least 8 min to prevent tissue
damage and sensitization. An ISI of at least 8min has been determined to
be sufficient to prevent paw sensitization during the use of this stimula-
tion method (McMullan et al., 2004; McMullan and Lumb, 2006a,
2006b; Leith et al., 2007; Ge´ranton et al., 2009; Hughes et al., 2013; Leith
et al., 2014). In addition, a feedback-controlled cutoff was set at 58°C for
fast thermal ramps and 55°C for slow thermal ramps. In recordings in
which thermal ramps reached cutoff temperature with no observable
EMG activity, threshold was recorded as cutoff2°C (Leith et al., 2007).
Experimental protocols and data analysis
EMG experiments. Naive and arthritic (7 d) animals were anesthetized and
underwent preparatory surgery for acute electrophysiological experiments
as described above. After 1 h of postsurgery rest (under continued anesthe-
sia), animals received alternating preferential A- and C-nociceptor stimula-
tion of the hindpawdorsumof the left leg. Alternating fast and slow thermal
ramps were delivered with an interstimulus of at least 8 min until 3 consec-
utive thresholds within2°C were achieved. The mean withdrawal thresh-
olds for A- andC-nociceptor activationwere calculated and then compared
between arthritic and naive animals. To assess effects of manipulating COX
and EP3R function on A- and C-nociceptor evoked EMG thresholds, some
animals underwent additional surgery and a craniotomy was performed as
described above to deliver drugs to the midbrain PAG. In some animals
(naive: 2 for vlPAG sulprostone, 5 for vlPAG GW671021B; arthritic: 4 for
dorsolateral PAG(dlPAG) sulprostone, 6 for vlPAGketoprofen, 7 for vlPAG
vehicle, 6 for vlPAG GW671021B) drug effects on EMG (withdrawal)
threshold to both A- and C-nociceptor activation were assessed in the same
animal.After rest,meanbaselinewithdrawal thresholds toalternatingA-and
C-nociceptor activation were determined as above. Once a stable baseline
had been established, a glass micropipette containing drug or control solu-
tionwas lowered vertically into the vlPAG ipsilateral to the stimulated hind-
paw. Solutions were injected into the PAG slowly (300 nl,	1 min) using a
custom-made paraffin-filled pressure injection system connected to a 1 l
syringe (Hamilton). Alternating A- and C-nociceptor stimulation of the ip-
silateral hindpaw was resumed at 1 min after drug delivery and withdrawal
thresholds measured up to 120 min after delivery. The order of A- and
C-nociceptor stimulationwas counterbalanced across experiments. In some
experiments, the effect of PAG-delivered drugs on EMG thresholds to A- or
C-nociceptor stimulationwas assessed separately in different rather than the
same animals. The numbers of animals in which only A- or C-nociceptor
stimulation was used were as follows: naive: 4 for vlPAG vehicle 
A-nociceptor stimulation, 5 for vlPAG vehicleC-nociceptor stimulation,
1 for vlPAG sulprostone A-nociceptor stimulation, 3 for vlPAG sulpros-
toneC-nociceptor stimulation, 1 for vlPAGGW671021BA-nociceptor
stimulation, 2 for vlPAGGW671021BC-nociceptor stimulation; and ar-
thritic: 1 for vlPAGGW671021BA-nociceptor stimulation. (BothA- and
C-stimulationwasused inother animals in eachexperimental group.)At the
end of the experiments, animals were killed by overdose with sodium pen-
tobarbital (30 mg, i.v. bolus; Sigma-Aldrich) and brains were dissected and
processed as described above for injection site localization.
The threshold temperature (in degrees Celsius) at which EMG activity
occurred was taken as the withdrawal threshold and was plotted against
time to display the time course of any drug or vehicle effects. In arthritic
EMG experiments, the timing of postdrug A- or C-nociceptor stimula-
tions varied between animals; that is, ISIs were often 	8 min due to
counterbalancing. To more accurately display the data, mean postdrug
stimulation and SEM values were calculated and plotted as x-axis error.
The same analysis was not performed for EMG experiments in naive
animals because postdrug A-/C-nociceptor stimulations were consis-
tently delivered with an ISI of 8 min. Finally, because our experimental
hypothesis specifically related to drug versus vehicle effects on EMG
thresholds rather than the time course of such action, individual net area
under the curve (AUC) for drug and vehicle effects were calculated from
baseline values for individual animals andmean net AUC comparedwith
determine specificity of drug actions.
Spinal neuronal electrophysiological experiments. Effects of intra-PAG
delivery of GW671021B/vehicle on action potential firing threshold of
spinal dorsal hornWDR neurons to peripheral A- or C-nociceptor stim-
ulation was assessed in 21 arthritic animals. Drug or vehicle effects on
WDR neuron firing thresholds to peripheral A- or C-nociceptor stimu-
lation were assessed in separate animals with an ISI of at least 10 min.
Functional classification of spinal WDR (class 2) neurons
WDRneuronswere located in arthritic animalsusing a low-threshold search
stimulus (brush, tap, prod) applied to the ipsilateral hindpaw to activate
spinal neurons while an electrode was tracked vertically down through the
spinal dorsal horn (250–1000mfromthedorsal surface of the spinal cord)
using an electronic microstepper. Once a cell was located and isolated, its
receptive field was mapped using low-threshold stimuli to ensure that its
excitatory receptive field could encompass the heat ramp contact area (	45
mm2). The spinal neuron was further characterized using limbmovement,
noxious, and non-noxious mechanical (26 g von Frey and brush) and nox-
ious cold (ethyl chloride) to determine the neuronal type (proprioceptive,
low-threshold, WDR, or nociceptive specific). Only cells that responded to
both low- and high-threshold stimuli (including heat) were characterized
further, corresponding to the class 2 neurons described previously (Mene´-
treyet al., 1977;Mene´treyet al., 1979).Nociceptive-specific (class3)werenot
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identified because a low-threshold search stimulus was used and therefore
no class 3 neurons were isolated.
Neuronal activity of class 2 neuronswas recorded continuously at 20K
samples/s using Spike2. A ‘wavemark’ template was created so that all
matching spikes from the same cell were written to a separate channel at
20 K samples/s. This channel was duplicated and displayed both as the
waveform of each event and as firing frequency from which the rate of
spontaneous activity and the responses of the cell to peripheral stimuli
could then be measured.
Spinal neuronal baseline responses to preferential A- or C-nociceptor
activation were determined by delivering three consecutive thermal
ramps by determination of the contact temperature at which single neu-
ronal firing was stimulated. Either A- or C-nociceptor activation alone
was used in each animal. During the ramping thermal stimulus, the
activation threshold was taken as the temperature at which the evoked
firing rate exceeded and remained elevated for	10% of the total stimu-
lus time (see Fig. 7). Spontaneous neuronal activity was calculated
over the period 10 to 5 s before the initiation of the thermal ramp
stimulus.
Once a stable baseline to heat stimulation was established (thresholds
within 2°C of each other) a glass micropipette containing drug (EP3R
antagonist GW671021B) or vehicle was lowered into the ipsilateral
caudal vlPAG and injected as described above. Preferential A- or
C-nociceptor activation was resumed 1 min after drug delivery and con-
tinued for 60 min with an ISI of at least 8 min. Mean (two to three
stimulations) baseline and postdrug/vehicle firing thresholds were plot-
ted against time to display the time course of any effects on spinal WDR
neurons. For consistency with analysis of EMG data, the overall drug or
vehicle effects onWDR firing threshold over the 60min of recording (net
AUC) were calculated and compared statistically to determine the spec-
ificity of drug actions.
Drugs
Stock solutions of all drugs (including vehicles) for microinjection were
made up in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at 10 mM and
stored at20°C until required. On the day of the experiment, an aliquot
was thawed and diluted to working concentrations in vehicle solution
(	90% PBS, 
10% DMSO and containing 3–5% w/v pontamine sky
blue dye tomark injection sites in electrophysiological experiments; 70%
physiological saline, 30% DMSO vehicle was used in behavioral experi-
ments). Despite some differences in DMSO concentration and the
addition of pontamine sky blue, the vehicle control injections used in
anesthetized and behavioral experiments produced no observable effects
on EMG, spinal neuronal firing threshold (see Figs. 2, 4, 6, 7), or paw
withdrawal threshold (see Fig. 1), respectively. All drugswere delivered in
a final volume of 300 nl with the final drug doses based on effective doses
as described by others and/or selectivity data for rat EP receptors. Drugs
were as follows: ketoprofen (nonspecific COX inhibitor) 10 mM (10%
DMSO); GW671021B 250 nM (
1%DMSO); rat EP3R antagonist selec-
tive over other EP, TP, FP, andDP receptors (Juteau et al., 2001; Belley et
al., 2006; Su et al., 2008)made in-house at GSK; sulprostone, 1 nM (
1%
DMSO); potent full EP3 agonist displaying activity at 
1 nM in the rat,
with only partial agonist activity at the EP1 receptor at doses considerably
higher than used here (Coleman et al., 1994; Boie et al., 1997).
Tissue isolation and PAG mRNA analysis
In five arthritic and five naive animals, tissue samples of the functional
PAG columns (ventrolateral and dorsolateral) were isolated from whole
PAG using a custom-built tissue puncher. Briefly, the sharp tip of a 21 G
needle (internal diameter 0.5mm;Terumo)was removed using aDremel
and cutting disk, the newly cut edge sharpened to create a cutting edge,
and the needle center bored out to create a tissue punch with an internal
diameter of 0.5 mm. Clean working habits were followed to prevent
contamination of the apparatus. The work area and apparatus was
cleaned with 70% alcohol before and after work was conducted on each
sample, a new apparatus (including microtome blade, cutting disk, and
slides) were used for each sample, and sterile disposables and filter pi-
pette tips were used whenever possible (e.g., gloves, needles, syringes,
etc.). Animals were killed with an overdose of intraperitoneal barbiturate
(60 mg/kg). Brains were dissected and the PAG removed with a clean
razor blade aided by a Perspex guide block (1 mm brain slicer; Zivic
Instruments). Using a freezing microtome, and with reference to images
from the rat brain atlas (Paxinos andWatson, 2006), 50msectionswere
cut from the caudal end of PAG to the level at which the ventrolateral
columns ended. At 8.3 mm from bregma, a 1-mm-thick section con-
taining vlPAG columns was carefully cut using the microtome, placed
onto a glass slide, and the sample flash frozen on dry ice. A second
1-mm-thick section (caudal end of the section 7.30 mm caudal to
bregma) was then made immediately at the point where the dlPAG is
clearly defined. Aided by a dissecting microscope, ventrolateral and dor-
solateral holes were punched out from respective sections using the pre-
made tissue puncher. Coordinates used were made with reference to the
rat brain atlas (Paxinos and Watson, 2006) to ensure tissue section con-
tained relevant PAG columns throughout its thickness. Each final
punched sample was 1mm thick with a 0.5 mm diameter. Clean syringes
and tissue punches were used for each sample. Samples were stored at
80°C until further processing.
Punched tissue samples from vlPAG and dlPAGwere homogenized in
1 ml of TRIzol/50 mg of tissue and RNA was extracted following the
manufacturer’s instructions. Extracted RNAwas treated with DNase I to
eliminate any genomic DNA and then reverse-transcribed using MMLV
reverse transcriptase. To detect COX-1, COX-2, and EP3RmRNA in the
vlPAG, PCR was performed (PTC-200 Peltier Thermal Cycler; MJ Re-
search) using previously published primers (Donaldson et al., 2001; Guo
et al., 2006; Myren et al., 2010) and cycling conditions shown in Table 1.
COX-2 primers were designed using the online primer design tool
PRIMER-BLAST. GAPDH PCR was used as an internal control and “no
RT” controls were included in all reactions to ensure that there was no
genomic DNA contamination of the samples. PCR products were run
and visualized (Gel Doc Ez Imager; Bio-Rad) on 2% agarose gels (w/v) in
Tris-acetate-EDTA buffer containing ethidium bromide. PCR ampli-
con intensities were quantitated using ImageJ. Data are shown as inten-
sity relative to GAPDH intensity in the same sample.
Statistics
All data are displayed as mean and SEM unless otherwise stated. Data
were tested for normality and results are reported in figure legends for
significant findings only. Shapiro–Wilk tests were used with groups of
sufficient size, but in some instanceswhere therewere smaller groups, the
Kolmogorov–Smirnov test was used, as stated in the figure legends. Nor-
mally distributed data with equal variance were compared using Graph-
Pad Prism (version 4/5) and paired/unpaired Student’s t test or ordinary
or repeated-measures one-way ANOVA followed by adjusted post hoc
tests for multiple comparisons, respectively, as detailed in the text. Two-
way ANOVA was used to compare the effect of drugs on EMG with-
drawal thresholds over time (see Figs. 2, 4, 6, 7), followed by post hoc tests
Table 1. PCR primers, conditions, and amplicon sizes
Target Primer sequences
Amplification conditions
(dehaturation, annealing,
extension, cycle number)
Amplicon size
(bp)
Cox-1 94°C 30 s 116
Upstream GGCGTTGCACATCCATCTACTC 50°C 30 s
Downstream AGCATCTGTGAGCAGTACCGG 72°C 60 s
35 cycles
Cox-2 94°C 30 s 98
Upstream GATGACGAGCGACTGTTCCA 45°C 30 s
Downstream TGGTAACCGCTCAGGTGTTG 72°C 60 s
35 cycles
EP3 94°C 30 s 144
Upstream GAGACGGCTATCCAGCTTAT 60°C 30 s
Downstream ATTGCACTCCTTCTCCTTTC 72°C 60 s
35 cycles
GAPDH 94°C 30 s 180
Upstream CAACTACATGGTTTACATGTTC 50°C 30 s
Downstream GCCAGTGGACTCCACGAC 72°C 60 s
35 cycles
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for multiple comparisons as detailed in the text and figure legends. For
two-way ANOVA, normality of data was assumed. If the data did not
meet the assumptions of parametric tests (non-Gaussian, unequal vari-
ances), then nonparametric test equivalents (Mann–Whitney U test,
Wilcoxon signed-rank test, Kruskal–Wallis test, or Friedman’s test) were
used, as stated in the figure legends. FormRNA expression data, normal-
ity was not tested or assumed and Mann–Whitney U tests were used to
determine the exact p-values. The probability at which significance was
accepted () was adjusted to account for the multiple tests used (two)
and therefore set at p 0.025 (p 0.05/2).
Results
Blockade of the PG EP3R within the vlPAGmodulates
withdrawal reflex thresholds in conscious naive rats
We have previously shown that inhibition of COX in the vl-
PAG increases paw withdrawal thresholds in both awake rats
(Leith et al., 2014) and anesthetized rats (Leith et al., 2007),
suggesting a tonic PAG COX-dependent pronociceptive sys-
tem. Delivery of the EP3R antagonist GW671021B into the
vlPAG increased thermal paw withdrawal thresholds com-
pared with both baseline and vehicle (EP3R antagonist base-
line vs postdrug 44.9 0.1 vs 45.9 0.2°C, vehicle baseline
vs postvehicle 44.4 0.3 vs 44.6 0.2°C; Fig. 1). Delivery of
GW671021B into the area outside of the PAG did not signifi-
cantly alter paw withdrawal thresholds (baseline vs post-
drug  44.9  0.3 vs 45.0  0.1°C; Fig. 1).
EP3Rs within the vlPAGmodulate withdrawal reflexes evoked
by peripheral C-nociceptor, but not A-nociceptor, activation
in naive rats
The EP3 agonist sulprostone injected into the vlPAG had no
effect on withdrawal thresholds evoked by A-nociceptor activa-
tion (Fig. 2A,E), but decreased the withdrawal threshold to
C-nociceptor activation comparedwith baseline (52.2 0.4°C to
a minimum of 49.5 0.5°C at t 33 min; Fig. 2B,F). Sulpros-
tone injection into the dlPAG had no effect on either A- or
C-nociceptor withdrawal thresholds [A-nociceptor: baseline
(55 0.8°C) vs 15min (54 3.2°C) vs 45min (56 0.9 °C) vs 90
min (54 1.4°C) post drug; C-nociceptor: baseline (55 1.1°C)
vs 15 min (57 0.3°C) vs 45 min (54 1.5°C) vs 90 min (54
1.9°C) postdrug, n  3 for both]. The EP3R antagonist
GW671021B had no effect on withdrawal thresholds evoked by
A-nociceptor activation (Fig. 2C,E), but increased thewithdrawal
threshold to C-nociceptor activation compared with baseline
(52 0.4°C to 56 0.4°C at t 33min; Fig. 2D). Comparison of
the overall effect of the two compounds, the EP3R agonist sulpr-
ostone and the EP3R antagonist GW671021B, confirmed that
they had no significant effect onA-nociceptor evokedwithdrawal
thresholds compared with vehicle (AUC EP3 agonist vs AUC
vehicle10.0 43.7 vs 41.4 24.0°C  min, AUC EP3 antag-
onist vs AUC vehicle  89.9  41.1 vs 41.4  24.0°C  min; Fig.
2E). The effects of EP3 agonist and EP3 antagonist on C-nociceptor
evokedwithdrawal thresholdswere significantly greater than vehicle
(AUC EP3 agonist vs AUC vehicle  164.6  38.50°C  min vs
6.2  18.50°C  min, AUC EP3 antagonist vs AUC vehicle 
302.9 39.27 vs 6.2 18.50°C  min; Fig. 2F).
CFA-induced knee joint arthritis leads to a secondary
hyperalgesia and allodynia of the hindpaw associated with an
enhanced spinal processing of A-nociceptor, but not C-
nociceptor, inputs
As shown previously on many occasions (Rees et al., 1996; Mar-
tindale et al., 2007), knee joint inflammatory arthritis resulted in
an increase in joint swelling (mesio-lateral distance measured
across the joint, baseline vs 7 d 7.6 0.2 vs 9.1 0.2 mm; Fig.
3A). The thickness of the hindpaw of the inflamed limb did not
change in size as a result of knee joint inflammation (baseline vs
7 d 4.1 0.1 vs 4.2 0.1 mm, p 0.118; Fig. 3B). Inflamma-
tory arthritis led to a significant fall in hindpaw thermal with-
drawal latency (Fig. 3C), as described previously (Davis et al.,
1994; Vermeirsch et al., 2007) apparent at 24 h and persisting for
at least 7 d (baseline vs 24 h vs 7 d withdrawal latencies 12.4
0.4 vs 8.1 0.5 vs 8.3 0.4 s, respectively; Fig. 3C). Arthritis also
resulted in a significant hindpaw mechanical allodynia over the
same time frame (baseline vs 24 h vs 7 d withdrawal thresholds
22 2 vs 14 4 vs 4 1 g, respectively; Fig. 3D) and a decrease
in the weight borne on the inflamed limb (baseline vs 7 d 49
0.5 vs 23 1.5%; Fig. 3E).
As we have also shown in a different cohort of animals using
the same model (Hsieh et al., 2015), anesthetized arthritic ani-
mals had significantly lower withdrawal thresholds only to
A-nociceptor stimulation in the hindpaw, the secondary hyper-
algesic site (A-nociceptor-evoked withdrawal threshold naive vs
arthritic, secondary hyperalgesia  57  0.2 vs 54  0.3°C, re-
spectively; Fig. 3F). C-nociceptor-evoked withdrawal thresholds
were unchanged in arthritic rats (naive vs arthritic 54 0.2 vs
54 0.1°C, p 0.266; Fig. 3F).
vlPAG is the site of prostanergic descending facilitation in the
anesthetized inflamed rat
We have found previously that the vlPAG, and not the dlPAG,
forms the site of prostanergic descending facilitation in the naive
anesthetized rat (Leith et al., 2007). To determine whether a sim-
ilar anatomical delineation extended to arthritic animals, the
nonspecific COX inhibitor ketoprofen was injected into the dl-
PAG and vlPAG to determine its effects on EMG withdrawal
thresholds to A- or C-nociceptor activation in the area of second-
ary hypersensitivity. Ketoprofen injected into the dlPAG had no
effect on withdrawal thresholds to either A- or C-nociceptor ac-
tivation [A-nociceptor baseline (55  0.7°C) vs 9.5 min (55 
0.7°C) vs 42.5min (54 0.7°C) vs 75min (52.7 0.8°C); Fig. 4A;
C-nociceptor baseline (52.7 0.5°C) vs 5.3min (53.0 0.9°C) vs
38.8min (52.7 0.5°C) vs 86.3min (53 0.6°C); Fig. 4B]. These
datasets had low variability, but also low numbers of animals,
which would not allow for variability to be seen if present. We
performed post hoc power calculations and determined that the
actual power of these experiments was 0.99 (both A- and
Figure 1. Blockade of EP3 signaling within the vlPAG increases thermal withdrawal thresh-
old in the awake naive rat. Delivery of the PG E2 EP3R antagonist (GW671021B) to the vlPAG
increased thermal withdrawal thresholds evoked from the hindpaw (Kruskal–Wallis test p
0.002, H 18.64 with Dunn’s post hoc test, **p
 0.01, *p
 0.05, Shapiro–Wilk normality
test for EP3 antagonist postdrug data, p 0.006, W 0.72; vehicle, n 6; EP3R antagonist,
n 7; outside PAG, n 3).
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C-stimulation). Sample size calculations using the data gen-
erated in these experiments also suggested that 22 animals
(A-nociceptor stimulation) and 48 animals (C-nociceptor stim-
ulation) would be necessary to see statistical significance on these
measures. We therefore concluded that any fluctuations in mea-
sures in these experiments were not likely to be physiologically
significant and that the lack of effect of ketoprofen in the dlPAG
is a true negative rather a type II statistical error.
When delivered into the vlPAG, ketoprofen increased with-
drawal thresholds to both A- and C-nociceptor stimulation (A-
nociceptor baseline vs 74min 52.8 0.6 vs 57.8 1°C, Fig. 4D;
C-nociceptor baseline vs 72.5min 52.6 0.6 vs 55.8 0.7, Fig.
4C). The effect of vlPAG ketoprofen on withdrawal thresholds to
A- and C-nociceptor stimulation was significantly greater than
vehicle injection (A-nociceptor AUC vlPAG ket vs AUC vlPAG
vehicle  375.6  66.1 vs 61.1  33.0°C  min, Fig. 4E;
C-nociceptor AUC vlPAG ket vs AUC vlPAG vehicle 239.0
45.6 vs 3.9  34.5°C  min; Fig. 4F). The vlPAG expression of
COX-1 was increased (Fig. 5A), but COX-2 mRNA was un-
changed, in arthritic animals (Fig. 5B). Surprisingly despite the
Figure 2. In the anesthetized naive rat, modulation of vlPAG EP3R signaling affects the spinal processing of only C-nociceptor inputs.A,B, Injection of the EP3 agonist sulprostone into the vlPAG
decreased only C-nociceptor-evoked withdrawal thresholds (EMG responses) (two-way ANOVA main effect of treatment, p 0.0098, F(1,53) 7.19, Sidak’s post hoc test ns at all time points,
sulprostone n 3, vehicle n 4) (N.B. significance attributable entirely to the last three data points).B Two-wayANOVAmain effect of treatment p
 0.0001, F(1,92) 69.67, Sidak’s post hoc test
**p
 0.01, sulprostone n 5, vehicle n 5; B). C, D, Similarly, the EP3R antagonist GW671021B increased only C-nociceptor-evoked withdrawal thresholds (two-way ANOVA main effect of
treatment, p
 0.0001, F(1,100) 132.0, effect of time p 0.0016, F(12,100) 2.90, interaction p 0.005, F(12,100) 3.29with Sidak’s post hoc test ****p
 0.0001, ***p
 0.001, **p
 0.01,
*p
 0.05, GW n 6, vehicle n 4; GW, n 6; vehicle, n 5). E, The overall effect of agonist and antagonist onA-nociceptor-evokedwithdrawalswas not significantly larger than that of vehicle
(one-way ANOVA of AUC in A and C, p 0.27, F(2,10) 1.49). F, Conversely, the overall effect of agonist and antagonist on C-nociceptor-evoked withdrawals was significantly different from that
of vehicle (one-way ANOVA of AUC in B and D, p
 0.0001, F(2,14) 47.27 with Bonferroni’s post hoc test, ****p
 0.0001, *p
 0.05).
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lack of functional effects on nociceptive reflexes of COX inhibi-
tion in the dlPAG, COX-1 mRNA was upregulated, and COX-2
mRNA downregulated in the dlPAG of arthritic animals.
In the anesthetized arthritic rat, vlPAG EP3R antagonism
affects the spinal processing of both A- and C-nociceptor
inputs from an area of secondary hypersensitivity
EP3R antagonist reversed the lowered withdrawal thresholds
to A-nociceptor activation in the hindpaw area of secondary
hypersensitivity in arthritic rats (baseline vs postdrug 
53.8  0.5°C vs 58.7  0.7°C at 4.5 min postdrug; Fig. 6A).
Thresholds were raised to higher values than those seen in
naive animals (cf. Figs. 2C, 6A) and the overall effect of EP3R
antagonist was significantly greater in inflammatory sec-
ondary hypersensitivity compared with naive animals (A-
nociceptor AUC naive vs AUC arthritic  89.9  41.1 vs
375.6  66.1°C  min; Fig. 6D). In contrast, the prostanergic
facilitatory tone on C-nociceptor reflex withdrawal thresholds
Figure 3. CFA-induced knee joint inflammation leads to behavioral secondary hyperalgesia and allodynia of the hindpaw. A, B, A single intra-articular knee joint injection of CFA (100l) leads
to an increase in the width of the knee joint (Wilcoxon’s signed-rank test, W28.0, p 0.016, Shapiro–Wilk normality test for naive data, W 0.58, p 0.002; n 7; A), but not in the
hindpaw (unpaired t test, p 0.11, t 1.8, df 8, n 5; B). C, D, Knee joint inflammation produced a reduction in the withdrawal threshold to both thermal (C) and mechanical (D) stimuli
delivered to the plantar surface of the hindpawof the inflamed limb [repeated-measures ANOVA, p
 0.0001 (for both), F(3,18) 39.69 (for C) and F(3,18) 14.80 (forD) with Bonferroni’s post hoc
tests, ****p
 0.0001, ***p
 0.001, *p
 0.05, n 7/group). E, Knee joint inflammation leads to a persistent reduction in the weight borne on the inflamed limb (Friedman test, Q 21.99,
p
 0.0001 followed by Dunn’s multiple-comparison test, **p
 0.01, ***p
 0.001, Shapiro–Wilk normality test for day 0 data, W 0.78, p 0.005, n 11). F, Withdrawal threshold to
preferential A-nociceptor, but not C-nociceptor, activation was significantly lower in secondary sites in arthritic animals versus naive animals (one-way ANOVA, p
 0.0001, F(3,60) 39.26 with
Bonferroni’s post hoc test ****p
 0.0001, n 16).
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seen in naive animals was maintained at the same level in
secondary hypersensitivity as seen in naive animals, as intra-
vlPAG EP3R antagonist increased withdrawal thresholds to
C-nociceptor activation (baseline vs postdrug 53.0 0.8°C
vs 56  1.0°C at 60 min postdrug; Fig. 6B) to a degree equiv-
alent to that seen in the naive animals (C-nociceptor AUC
naive vs AUC arthritic  302.9  39.27 vs 239.0 
45.6°C  min; Fig. 6D). The overall effect of EP3R antagonism
on A- and C-nociceptor-evoked thresholds in inflammatory
secondary hypersensitivity was equivalent in inflammatory ar-
thritis and significantly greater than vehicle (EP3R
A-nociceptor vs vehicle A-nociceptors  375.6  66.1 vs
61.1  33.0°C  min, EP3R C-nociceptor vs vehicle C-noci-
ceptors  239.0  45.6 vs 3  34.5°C  min; Fig. 6C). EP3R
mRNA expression was unchanged in vlPAG in arthritis. Like
COX-1, EP3R mRNA was upregulated in the dlPAG in ar-
thritic rats (Fig. 5C).
In the anesthetized arthritic rat, vlPAG EP3R antagonism
modulates spinal dorsal horn neuronal responses to C- but
not A-nociceptor inputs from an area of secondary
hypersensitivity
Intra-vlPAG EP3R antagonist had no effect on the firing
threshold of WDR neurons in knee arthritic rats to preferen-
tial A-nociceptor activation on the hindpaw [baseline (46.0
1.2°C) vs 10 (45.83  1.49°C) vs 30 (45.17  1.89°C) vs 60
Figure 4. In the arthritic rat, the ventrolateral and not the dorsolateral columns of the PAGmediate prostanergic effects on spinal nociception. A, B, Ketoprofen injected into the dlPAG
had no notable effect on EMG-derived withdrawal thresholds to preferential A- and C-nociceptor activation in the hindpaw secondary site (n 4 for both groups). C, D, Ketoprofen
injected into the vlPAG increased withdrawal threshold to A- and C-nociceptor activation in the hindpaw secondary site (C: two-way ANOVA main effect of treatment p
 0.0001, F(1,89)
 26.23, effect of time p 0.0051, F(8,89) 2.99, interaction p 0.0061, F(8,89) 2.92 with Sidak’s post hoc test **p
 0.01, *p
 0.05, n 7 for vehicle and n 6 for ketoprofen;
D: two-way ANOVA main effect of treatment p
 0.0001, F(1,88) 40.57, effect of time p 0.048, F(7,88) 2.13 with Sidak’s post hoc test ***p
 0.001, *p
 0.05, n 5 for
ketoprofen, n 7 for vehicle). E, Ketoprofen injected into the vlPAG had a significantly greater effect on EMG thresholds evoked by A-nociceptors than that of a vehicle injection. In
addition, when delivered into the vlPAG, ketoprofen had a significantly greater effect on EMG thresholds evoked by A-nociceptors comparedwith delivery into the dlPAG (one-way ANOVA
p 0.0001, F(2,14) 18.98 with Bonferroni’s post hoc test ***p
 0.001, **p
 0.01; n 4 for dlPAG, n 6 for vlPAG ket, n 7 for vlPAG vehicle). F, Ketoprofen injected into the
vlPAG had a greater effect on EMG thresholds evoked by C-nociceptor activation than that of vehicle. In addition, when delivered into the vlPAG, ketoprofen had a greater effect on EMG
thresholds evoked by C-nociceptor activation compared with delivery into the dlPAG (one-way ANOVA p 0.0012, F(2,13) 11.83 with Bonferroni’s post hoc test **p
 0.01; n 4 for
dlPAG, n 5 for vlPAG ket, n 7 for vlPAG vehicle).
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(43.67 0.67°C) mins postdrug, evoking responses at thresh-
olds similar to those previously reported (McMullan and
Lumb, 2006a; Leith et al., 2014); Fig. 7A,C,E]. In contrast,
EP3R antagonist increased neuronal firing threshold in re-
sponse to preferential activation of hindpaw C-nociceptors
(baseline vs 20 min postdrug  45.7  1.4°C and 51.0  2°C;
Fig. 7B,D,E). The effect of EP3R antagonism was significa-
ntly greater on C-nociceptor compared with A-nociceptor
responses and significantly greater than vehicle (EP3
C-nociceptor vs EP3 A-nociceptor  175.7  39.75 vs
39.17  48.76°C  min; EP3 C-nociceptor vs vehicle C-no-
ciceptor  175.7  39.7 vs 38.73  55.7°C  min; Fig. 7E).
The thresholds of evoked EMG withdrawals are higher than,
but encompass the range of, thresholds of WDR neurons in this
study, (e.g., A-nociceptor evokedWDR firing threshold range
42–55°C; A-nociceptor evoked EMG thresholds  52–56°C).
Values for EMG and WDR thresholds are consistent with
our previous studies (Leith et al., 2007; Leith et al., 2014).
Hindlimbwithdrawal requires coordinated, integrated activity in
a multineuronal pathway spanning dorsal and ventral horns,
which includes contributions from low-threshold, WDR, and
nociceptive-specific neurons, not WDR neurons alone. There-
fore, the threshold for limbwithdrawal (EMG activity) is likely to
be higher than any single neuronwithin that circuitry and should
be closest to those spinal neurons with the highest thresholds
(e.g., nociceptive specific neurons). It should also be noted that
the anesthetic alphaxalone augments GABAergic inhibition,
which will affect network function and exert a cumulative effect
on the polysynaptic withdrawal reflex pathway. Both of these
actions might be expected to raise EMG thresholds relative to
WDR action potential firing thresholds.
Discussion
COX–PG signaling has well described pro-nociceptive and anti-
nociceptive effects at peripheral and spinal sites, but its actions at
supraspinal sites are less well defined. The PAG expresses both
COX isoforms (Fig. 5; Breder et al., 1992; Breder et al., 1995) and
the PG EP receptors EP1–4, although precise cellular localiza-
tions are still unclear (Palazzo et al., 2011;Myren et al., 2012). The
vlPAG, rather than other PAG subregions, exerts a specific facili-
tatory effect over spinal nociceptive processing in naive animals
(Heinricher et al., 2004; Leith et al., 2007; Palazzo et al., 2011) and
in acute inflammatory and neuropathic models (Oliva et al.,
2006; Palazzo et al., 2011).
Central inhibition of COX in lateral PAG (Tortorici and
Vanegas, 1995) and rostroventral medulla contributes to de-
scending inhibition through potentiation of opioid analgesia
(Vaughan et al., 1997; Vaughan, 1998). Cannabinoid-stress-
induced analgesia derives from multiple PAG columns (Licht-
man et al., 1996; Olango et al., 2012) and can be engaged by
intra-PAG COX inhibition (Vanegas et al., 2010). Our data
are, however, consistent with a discrete endogenous vlPAG
prostanergic-EP3R receptor mechanism directly facilitating spi-
nal C-nociceptive processing in conscious and anesthetized naive
animals and A-nociceptive processing in hindpaw secondary hy-
persensitivity in arthritic animals. Hindpaw secondary hypersen-
sitivity occurs in knee-joint arthritis (Herrero and Cervero, 1996;
Urban et al., 1999; Zhang et al., 2002; Martindale et al., 2007),
with sensitization of the spinal processing of A-nociceptor inputs
(Fig. 3F; Hsieh et al., 2015). De novo central A-nociceptor sensi-
tization is dependent on intra-vlPAG PGs, most likely PGE2, be-
cause it is reversed with the EP3R antagonist.
The absence of effect of vlPAG EP3R antagonism onA-nocicep-
tor-evokedWDR firing thresholds in arthritic animals was surpris-
ing considering the clear sensitization of A-nociceptor-evoked
noxious withdrawals. Deep dorsal horn WDR neurons are integral
to spinal reflex circuitry and activity inWDR neurons is well corre-
lated with motor unit activity during withdrawal (You et al., 2003),
hence the targeting of WDR neurons in this study. One interpreta-
tionof our findings is that the effects onA-nociceptor processing are
Figure 5. COX enzyme and EP3R mRNA expression are regulated within the PAG after knee
joint arthritis. A, COX-1 mRNA expression was significantly increased in both vlPAG and dlPAG
7 d after induction of knee joint arthritis [Mann–Whitney U 0 (sum of ranks, 15, 30; vlPAG)
and U 1 (16,39; dlPAG), p 0.016 for both ( 0.025, corrected for multiple compari-
sons)]. B, COX-2 mRNA expression was significantly decreased in dlPAG [U 0 (40, 15), p
0.008], but unchanged in vlPAG [U 3 (18, 27), p 0.11]. C, EP3 mRNAs had a tendency to
increase in vlPAG [U 2 (17, 28), p 0.06] and was significantly increased in dlPAG [U 1
(16, 39), p 0.02].
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mediated in the ventral rather than dorsal horn. The PAGhas direct
projections to the lumbar spinal ventral horn despite themajority of
PAG projections targeting the cervical cord (Mouton andHolstege,
1994).We consider an action in the ventral horn to be unlikely as if
the additional facilitation of A-nociceptor processing observed in
arthritic animals weremediated at the level of the ventral horn then
similar effects on C-nociceptor processing would be expected (Fig.
6D). Because A- and C-nociceptor information is integrated at this
spinal level, it is therefore more likely that effects on A-nociceptive
processing inarthritic animals aremediated throughalternativedor-
sal horn neuronal populations, such as nociceptive-specific and/or
WDRneurons located in superficial laminae.Descending inhibitory
pathways originating from the vlPAGmodulate both A- and C-no-
ciceptor evoked c-fos expression in superficial laminae (indicative of
spinal neuronal activation), but affect only C-nociceptor-evoked c-
fos expression in deeper laminae (Koutsikou et al., 2007).
Peripheralnociceptors innervating secondary sitesdonotdisplay
significant sensitization (Baumann et al., 1991; LaMotte et al., 1992;
Torebjo¨rk et al., 1992; also seeSerra et al., 2004).Thedevelopmentof
secondary hypersensitivity is critically dependent on central sensiti-
zation, including potentiation of synaptic efficacy, and engagement
of descending controls (Urban et al., 1999; Sandku¨hler, 2009; Naka
et al., 2013). Our findings are consistent with the hypothesis that
activity in capsaicin-sensitive C-nociceptors (McMullan et al., 2004;
Leith et al., 2007) innervating the areaof tissuedamagedrives central
sensitization (Woolf, 1983; Leith et al., 2007; You et al., 2010) and
facilitates the spinal processing ofA-nociceptor inputs fromsecond-
ary sites, in part through descending facilitation (LaMotte et al.,
1992; Treede et al., 1992; Magerl et al., 2001; Hsieh et al., 2015).
Interpretation of these findings is, however, dependent on the selec-
tivity of the heat-ramp stimulation. If a significant number of
A-nociceptorswere also activatedby slowramps, thenwewouldalso
expect to see facilitation of slow-ramp-evoked reflexes in secondary
hypersensitivity,whichwedonot. In addition, capsaicin, a sensitizer
of TRPV1-expressing C-nociceptors, affects only slow-ramp re-
sponses;DMSO, a sensitizer ofA-nociceptors, affects only fast-ramp
responses. In WDR neurons, the magnitude of C-fiber response to
electrical stimulation correlates with the response to slow-ramp ac-
tivation (Leith et al., 2007). This evidence suggests that this method
activates cutaneous C- and A-nociceptor populations preferentially
(Yeomans and Proudfit, 1996).
Changes in the balance of descending inhibitory and facili-
tatory controls can reduce the threshold for long-term potentia-
tion (LTP) induction, allowing noxious stimuli that are usually
unable to drive central sensitization to do so (Sandku¨hler, 2009).
For instance, electrical stimulation of peripheral nerves at A-fiber
Figure 6. In the arthritic rat, EP3R antagonism in the vlPAG increases EMGwithdrawal thresholds to A- and C-nociceptor activation in the hindpaw secondary hypersensitive site. Injection of the
EP3 antagonist GW671021B into the vlPAG increased EMG thresholds evoked by preferential A-nociceptor and C-nociceptor activation in the hindpaw secondary site (A: two-wayANOVAmain effect
of treatment p
 0.0001, F(1,86) 38.53 with Sidak’s post hoc test **p
 0.01, *p
 0.05, n 6 for GW671021B and 7 for vehicle; B: two-way ANOVA main effect of treatment p
 0.0001,
F(1,78) 56.51, interaction p 0.41 F(7,78) 2.22 with Sidak’s post hoc test ****p
 0.0001, ***p
 0.001, **p
 0.01, *p
 0.05, n 5 for GW671021B and n 7 for vehicle). C, EP3R
antagonist had a greater effect on EMG thresholds evoked by A- and C-nociceptor activation than vehicle (one-way ANOVA p
 0.0001, F(3,21) 20.84with Bonferroni’s post test ****p
 0.0001,
**p
 0.01,n 6 and5 for EP3A- and C-nociceptor groups, respectively, andn 7 for both vehicle groups).D, Effect of the EP3R antagonist on EMG thresholds evokedby C-nociceptor stimulation
was equivalent in arthritic and naive animals. However, the effect of the EP3R antagonist on EMG thresholds evoked by A-nociceptor stimulation was greater in arthritic versus naive animals
(one-way ANOVA p 0.0037, F(3,20) 6.2 with Bonferroni’s post test, **p
 0.01; n 6 for A-nociceptor naive and arthritic, n 7 for C-nociceptor naïve, and n 5 for C-nociceptor arthritic).
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Figure 7. In the arthritic rat, EP3R antagonism in the vlPAG increases the firing threshold of spinal dorsal horn WDR neurons to C-nociceptor, but not A-nociceptor, activation in the hindpaw
secondary hypersensitive site. A,B, Example traces of spinal WDR neuronal recordings and their responses to peripheral A-nociceptor (A) and C-nociceptor (C) activation before (baseline) and after
injection of the EP3R antagonist into the vlPAG. Digitized data traces show: firing frequency of sorted spikes of individual WDR neurons, examples of action potential spike trains of spinal WDR
neurons from which the firing frequency traces are derived, and changes in hindpaw dorsum contact skin temperature in response to the ramping thermal stimuli used to activate A- and
C-nociceptors preferentially. Horizontal cursors in on firing frequency tracesmark themean firing rate in the 10 s preceding the start of thermal stimulus (e.g., 0.1 and 0.9 Hz inA). The thermal firing
threshold is taken at the point in which thermally evoked activity exceeded themean baseline firing rate and remained elevated for at least 10% of the total duration of thermal stimuli (shown by
the vertical cursors (1) in A and B). WDR neuron thermal firing threshold temperatures (in degrees Celsius) are thus indicated using the horizontal cursors in skin contact temperature trace (e.g.,
44.4°C and 43.1°C in A) as the skin temperature at which these conditions are met. Digitized data examples for both baseline responses and after EP3R antagonist (Figure legend continues.)
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strength produces LTP at C-fiber synapses only when descending
controls are disrupted (Liu et al., 1998). C-nociceptive drive
from the primary injury site may affect the spinal processing of
A-nociceptor inputs from the secondary sites through both
spinal and supraspinal mechanisms because C-nociceptors ter-
minate exclusively in the superficial dorsal horn and drive spinal–
supraspinal–spinal loops via spinal projection neurons (Light
and Perl, 1979; Suzuki et al., 2002; Mantyh and Hunt, 2004).
Importantly, heterosynaptic LTP of synaptic efficacy may un-
mask and/or increase A-fiber drive to spinal nociceptive circuits.
This could lead to the central sensitization to A-fiber inputs.
Descending facilitation from the rostral ventral medulla (RVM)
is critical for the maintenance of secondary hyperalgesia in ro-
dents (Urban and Gebhart, 1999) and, notably, PG signaling
within the vlPAG modulates RVM ON and OFF cell activity in
naive and neuropathic rats (Heinricher et al., 2004; Palazzo et al.,
2011). This suggests that a spinal/PAG/RVM/spinal loop under-
pins the vlPAG-prostanergic facilitatory pathway.
Secondary hypersensitivity is often suggested to be limited to
mechanical stimulation (Treede et al., 1992) because inflammatory
secondary thermalhyperalgesia is notpresent in the capsaicinmodel
(Raja et al., 1984; Ali et al., 1996). However, secondary thermal hy-
persensitivity is sometimes, but not always (Pertovaara, 1998), re-
ported in clinical studies (Bajaj et al., 2001; Schaible et al., 2009) and
experimental studies (Fig. 3C; Herrero and Cervero, 1996; Urban et
al., 1999; Zhang et al., 2002; Martindale et al., 2007; Hsieh et al.,
2015), so it is more likely that secondary hypersensitivity is a central
A-nociceptor-sensitization, not a modality-specific (thermal/
mechanical) process (Hsieh et al., 2015).
Although peripheral C-nociceptors are not sensitized in sec-
ondary sites (Baumann et al., 1991; LaMotte et al., 1992; Toreb-
jo¨rk et al., 1992), C-nociceptor-evoked reflexes and neuronal
responses are reported to be facilitated at secondary sites (Her-
rero and Cervero, 1996; Martindale et al., 2007). However, this
may represent a potential confound of electrical C-fiber stimula-
tion parameters in inflamed animals. The simplest interpretation
of our finding of unchanged C-nociceptor-evoked reflexes in ar-
thritic animals is that there is no additional facilitation of
C-nociceptive inputs from secondary sites, in contrast to the ef-
fect on A-nociceptive processing.
In vlPAG, COX-1 mRNA levels are altered, suggesting that ex-
tension of the prostanergic facilitation to A-nociceptor inputs may
result from increased intra-vlPAG COX-1-dependent PG produc-
tion acting on EP3R. Altered CNS COX expression has been attrib-
uted to increasedcentral interleukin-1beta (IL-1beta) levels found in
inflammatory arthritis in humans and animals (Samad et al., 2001;
Kosek et al., 2015). IL-1beta exerts different effects in different re-
gionsof thebrain (Anet al., 2011), for example, increasedexpression
of COX-1 in perivascular, endothelial, and glial cells (García-Bueno
et al., 2009;Matouseket al., 2010);COX-2expression inmultiple cell
types including neurons (Crofford et al., 1994; Serou et al., 1999;
Samad et al., 2001); and EP3Rs onCNS glial cells (Waschbisch et al.,
2006). Intra-vlPAGEP1receptors are implicated in the facilitationof
neuropathic pain; surprisingly, these receptors are reportedly down-
regulated but remain functional in this condition (Palazzo et al.,
2011).
Although COX-1, COX-2, and EP3R expression is regulated
in the dlPAG in inflamed rats, inhibition of this system in dlPAG
had no effect on nociceptive processing. The dlPAG is implicated
in active rather than passive behavioral responses to stress/fear,
including autonomic control of breathing and cardiovascular
function (Dampney et al., 2013). There is no published evidence
linking COXs and/or PGs with any dlPAG functional responses,
although PGE2 modulates dlPAG neuronal function by EP3R-
dependent inhibition of glutamatergic inputs (Lu et al., 2007).
Here, we have demonstrated that descending facilitation from
the PAG affects nociceptive processing in awake animals through
intra-vlPAG EP3R signaling. In the naive state, this descending
facilitation is restricted to the spinal processing of C-nociceptive
inputs, but extends to affect A-nociceptive inputs from secondary
sites in arthritic animals. Prostanergic descending facilitation
from the PAGmay provide a major contribution to mechanisms
of central sensitization that is critical to the inflammatory pain
phenotype. These data suggest that, for centrally penetrating
NSAIDs at least, their principle analgesic effect may be to reduce
descending facilitation, rather than alter spinal processing, where
EP receptors may exert anti-nociceptive effects (Ba¨r et al., 2004;
Natura et al., 2013). This may account for the ineffectiveness of
spinally delivered NSAIDs in humans (Eisenach et al., 2010a;
Eisenach et al., 2010b).
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